VetSheet

伊巴沙星

Ibafloxacin

抗生素 - 氟喹諾酮類PO

別名: Ibaflin · S-25030

由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本

15 mg/kg PO once dailyPO· q24h· Usually a 10-day course is sufficient. In cases of deep pyoderma, reconsider treatment if sufficient improvement not seen in 21 days.
🐕

劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。

各物種劑量

🌎 NA — North America🌍 EU — Europe

適應症劑量途徑頻次療程地區
Susceptible infections (dermal infections: superficial and deep pyoderma, wounds, abscesses)15 mg/kg PO once dailyPOq24hUsually a 10-day course is sufficient. In cases of deep pyoderma, reconsider treatment if sufficient improvement not seen in 21 days.🌎 NA
  • Susceptible infections (dermal infections: superficial and deep pyoderma, wounds, abscesses): Give at time of feeding. Reconsider treatment if no improvement after 5 days.

適應症劑量途徑頻次療程地區
Susceptible infections (dermal infections: soft tissue infections-wounds, abscesses; upper respiratory tract infections)15 mg/kg PO once dailyPOq24hUsually a 10-day course is sufficient.🌎 NA
  • Susceptible infections (dermal infections: soft tissue infections-wounds, abscesses; upper respiratory tract infections): Give at time of feeding. Reconsider treatment if no improvement after 5 days.

劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。

正在看診?VetSheet 的 AI 會把藥物、劑量與療程直接寫入結構化的看診紀錄。了解 VetSheet 如何運作

概覽

伊巴沙星 (Ibafloxacin) 是一種獸醫專用的口服​氟喹諾酮類抗生素​,主要在歐洲使用(美國未上市)。它對多種革蘭氏陰性菌和部分革蘭氏陽性菌(如腸桿菌科、葡萄球菌)具有​濃度依賴性的殺菌活性​

​臨床要點​:與其他氟喹諾酮類藥物(如恩諾沙星或馬波沙星)不同,它對綠膿桿菌 (Pseudomonas)、鏈球菌 (Streptococcus) 和奇異變形桿菌 (Proteus mirabilis) 的療效較差。

值得注意的是,目前​沒有證據顯示它會引起貓的視網膜毒性​,這是相較於同類某些藥物的一大優勢。

作用機轉

Fluoroquinolones exert their bactericidal effect by targeting essential bacterial enzymes involved in DNA replication and transcription.

  • Primary Target: Inhibits bacterial DNA-gyrase (topoisomerase II) → prevents DNA supercoiling → halts DNA synthesis.
  • Secondary Target: Inhibits topoisomerase IV → interferes with the separation of interlinked replicated DNA molecules.

Ibafloxacin is metabolized into two active metabolites (8-hydroxy-ibafloxacin and 7-hydroxy-ibafloxacin), which contribute to its overall antimicrobial efficacy.

安全性與警告

禁忌症

  • Dogs less than 8 months of age
  • Giant breed dogs less than 18 months of age
  • Cats less than 8 months of age
  • Known quinolone hypersensitivity

不良反應

  • Diarrhea
  • Soft feces
  • Vomiting
  • Dullness
  • Anorexia
  • Salivation
  • Elevated hepatic enzymes (rare, class effect)
  • Ataxia (rare, class effect)
  • Seizures (rare, class effect)
  • Depression/Lethargy (rare, class effect)
  • Nervousness (rare, class effect)

注意事項

Use should be based upon susceptibility testing. Safety has not been established in pregnant cats or in lactating dogs and cats, though the UK label states it can be used during pregnancy in dogs. Use with caution in patients with central nervous system disorders.

藥物交互作用

NSAIDs

Should not be used with NSAIDs in dogs with a history of seizures due to increased risk of CNS stimulation.

Antacids or Supplements (iron, zinc, magnesium, aluminum, calcium)

Cations may bind to ibafloxacin and prevent its gastrointestinal absorption.

Cyclosporine

Fluoroquinolones may exacerbate the nephrotoxicity of systemic cyclosporine.

Nitrofurantoin

May antagonize the antimicrobial activity of fluoroquinolones; concomitant use is not recommended.

Quinidine

Increased risk for cardiotoxicity.

Sucralfate

May inhibit absorption of ibafloxacin; separate doses by at least 2 hours.

Theophylline

Ibafloxacin may increase theophylline blood levels.

監測

  • Clinical efficacy
  • Adverse GI effects (vomiting, hypersalivation, diarrhea, anorexia)

藥物動力學

半衰期

5.2 hours

吸收

Dogs: Oral bioavailability is 70-80% with peak levels at ~1.5 hours. Cats: Rapidly absorbed; food slightly delays absorption but doubles peak levels and increases AUC compared to fasted administration.

分佈

Dogs: Volume of distribution at steady state is 1.1 L/kg. Goats: Vd is 1.65 L/kg.

代謝

Presumably metabolized in the liver to at least two active metabolites: 8-hydroxy-ibafloxacin and 7-hydroxy-ibafloxacin.

排除

Eliminated in both urine and feces as unchanged drug and glucuronidated metabolites. Total clearance in dogs is 8.7 mL/min/kg.

過量

Specific information is limited. It is unlikely an acute overdose would result in signs more serious than anorexia or vomiting.

  • Dogs: Doses of 75 mg/kg/day (5X) were apparently well tolerated.
  • Cats: Doses up to 75 mg/kg/day demonstrated salivation and vomiting. If overdose occurs in cats, ophthalmic monitoring is recommended as a precaution, despite no reported ocular toxicity.

可用產品

劑型

  • Oral gel (3%, 7.5%)
  • Tablets (30 mg, 150 mg, 300 mg, 900 mg)

獸醫用

  • Ibaflin 3% Oral Gel (30 mg ibafloxacin per gram of gel; 30.9 mg/mL) in 15 mL dial syringes
  • 7.5% oral gel
  • Tablets: 30 mg, 150 mg, 300 mg, 900 mg

各地核准狀態

暫無法規資料: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

儲存與穩定性

The oral gel should not be stored at temperatures more than 25°C. Once opened, it is recommended that the syringe be used within 8 weeks. Dispose of unused product once a course of treatment is completed.

飼主須知

  • ​給藥方式​:請​隨餐​給予此藥物。
  • ​完整療程​:即使您的寵物看起來已經康復,也務必​完成整個處方療程​。提早停藥可能會導致細菌產生抗藥性。
  • ​副作用​:請留意輕微的腸胃不適(嘔吐、腹瀉、流口水或食慾不振)。如果這些症狀變嚴重或持續存在,請立即聯繫您的獸醫師。
  • ​儲存方式​:將口服凝膠保存在室溫下(低於 25°C),並在開封 8 週後丟棄任何剩餘的藥物。

VetSheet 藥物參考供合格獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠商最新仿單。